Outlook Therapeutics (OTLK) News Today $2.06 +0.04 (+1.98%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$2.06 0.00 (0.00%) As of 01/31/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Outlook Therapeutics names new chairman amid product launchJanuary 31 at 5:00 PM | msn.comOutlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of DirectorsJanuary 31 at 8:05 AM | globenewswire.comOutlook Therapeutics announces presentation of data from NORSE EIGHTJanuary 23, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMDJanuary 23, 2025 | globenewswire.comOutlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarJanuary 22, 2025 | globenewswire.comChardan Capital Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)January 21, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a research note on Friday.January 18, 2025 | marketbeat.comNew Hacking Disaster Warning For Gmail, Outlook, Apple Mail UsersJanuary 17, 2025 | forbes.comCritical Microsoft Outlook Vulnerability Rated 9.8/10 Confirmed—Update NowJanuary 17, 2025 | forbes.comPositive Outlook for Outlook Therapeutics Driven by Promising ONS-5010 Data and Strategic Market PositioningJanuary 17, 2025 | markets.businessinsider.comOutlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from GuggenheimGuggenheim restated a "buy" rating and set a $12.00 target price on shares of Outlook Therapeutics in a research note on Friday.January 17, 2025 | marketbeat.comOutlook Therapeutics' (OTLK) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Friday.January 17, 2025 | marketbeat.comShort Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7%Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) was the target of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,890,000 shares, a drop of 17.7% from the December 15th total of 3,510,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 18.0% of the shares of the stock are sold short.January 17, 2025 | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical TrialJanuary 17, 2025 | finanznachrichten.deOutlook Therapeutics’ ONS-5010 shown to be non-inferior to Lucentis in wet AMDJanuary 17, 2025 | markets.businessinsider.comOutlook Therapeutics enters into agreement for warrant inducement transactionJanuary 17, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical TrialJanuary 16, 2025 | globenewswire.comAnalysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $32.73Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assignedJanuary 16, 2025 | marketbeat.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has received an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendaJanuary 13, 2025 | marketbeat.comOutlook Therapeutics® Participates in Virtual Investor “What This Means” SegmentJanuary 8, 2025 | globenewswire.comOutlook Therapeutics provides ONS-5010/LYTENAVA updateDecember 28, 2024 | finance.yahoo.comOutlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration TreatmentDecember 27, 2024 | marketwatch.comOutlook Therapeutics reports FY24 EPS ($4.06) vs. ($4.72) last yearDecember 27, 2024 | markets.businessinsider.comOutlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate UpdateDecember 27, 2024 | globenewswire.comATX Ahead: 2025 Economic Outlook event coming in JanuaryDecember 18, 2024 | bizjournals.comOutlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial LaunchDecember 13, 2024 | marketwatch.comOutlook Therapeutics® Streamlines OperationsDecember 13, 2024 | globenewswire.comBTIG Reaffirms Their Buy Rating on Outlook Therapeutics (OTLK)December 11, 2024 | markets.businessinsider.comOutlook Therapeutics announces NICE recommendation of LYTENAVADecember 4, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDDecember 4, 2024 | globenewswire.comOutlook Therapeutics® Announces Executive Leadership TransitionDecember 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLKDecember 2, 2024 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)November 28, 2024 | markets.businessinsider.comOutlook Therapeutics Trial of Eye Disease Treatment Misses Key EndpointNovember 28, 2024 | marketwatch.comOutlook Therapeutics reports preliminary results from Norse Eight trialsNovember 28, 2024 | markets.businessinsider.comOutlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical TrialNovember 28, 2024 | markets.businessinsider.comOutlook plunges as lead asset fails in wet AMD studyNovember 28, 2024 | msn.comWhy Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?November 27, 2024 | benzinga.comGreat Point Partners LLC Sells 408,482 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)Great Point Partners LLC trimmed its holdings in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) by 24.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,293,028 shares of the company's stock aNovember 27, 2024 | marketbeat.comOutlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical TrialNovember 27, 2024 | globenewswire.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Buy" from BrokeragesOutlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has received a consensus rating of "Buy" from the seven analysts that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objectNovember 24, 2024 | marketbeat.comOutlook Therapeutics® to Present at the Guggenheim Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.comCautious Outlook on United Therapeutics Amid Revenue Growth and Competitive PressuresNovember 1, 2024 | markets.businessinsider.comULM College of Business and Social Sciences to host Outlook Summit at Bayou Pointe Event Center on November 8October 29, 2024 | msn.comPositive Outlook on Viking Therapeutics Driven by Promising VK2735 Obesity ProgramOctober 25, 2024 | markets.businessinsider.comOutlook Therapeutics: Poised to Capitalize on Market Opportunities with LYTENAVA Amidst Industry ShiftsOctober 19, 2024 | markets.businessinsider.comOutlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG ResearchBTIG Research reiterated a "buy" rating and set a $50.00 target price on shares of Outlook Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comOutlook Therapeutics® Participates in a Virtual Investor CEO Connect SegmentOctober 17, 2024 | finance.yahoo.comEconomic Outlook Conference will “Re-Imagine” the future of the Ohio ValleyOctober 12, 2024 | msn.comOutlook down? Microsoft confirms issues with email service, but a fix is now hereOctober 12, 2024 | yahoo.com Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address OTLK Media Mentions By Week OTLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLK News Sentiment▼0.720.69▲Average Medical News Sentiment OTLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLK Articles This Week▼44▲OTLK Articles Average Week Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TuHURA Biosciences News Today Greenwich LifeSciences News Today Cardiff Oncology News Today Acrivon Therapeutics News Today ProQR Therapeutics News Today INmune Bio News Today Aclaris Therapeutics News Today Zentalis Pharmaceuticals News Today Nkarta News Today Protalix BioTherapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OTLK) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
